Key Highlights

  • Third-quarter revenue is estimated at USD 22.62 billion, 28.5% above the year-earlier period.
  • The USD 88.68 billion full-year consensus exceeds guidance, which runs from USD 85 billion at the low end to USD 87 billion at the high end.
  • Depending on methodology, per-share forecasts span USD 5.38 to USD 6.67.
  • Options indicate a 6.6% move in either direction after shares declined about 3.3% on October 23.

Can Eli Lilly Raise Its Outlook Enough to Meet a USD 88.68 Billion Bar?

Eli Lilly (NYSE:LLY) releases third-quarter figures on October 29, 2026, a Thursday. Revenue consensus of approximately USD 22.62 billion implies 28.5% annual growth. For 2026, the USD 88.68 billion market estimate already tops guidance, whose lower and upper limits are USD 85 billion and USD 87 billion. Management has raised that range twice.

EPS projections differ by measure, ranging from USD 5.38 to USD 6.67. The normalized estimate has fallen from roughly USD 9.87 one month earlier. Five consecutive EPS beats and the gap between consensus and guidance mean a third sales-outlook increase may matter more than another profit beat.

Why Do Acquired Research Charges Create Such a Wide EPS Range?

Non-GAAP earnings include acquired IPR&D expense. Consequently, the upfront price of a drug candidate reduces EPS in the period when a transaction closes, making deal timing a major source of variation among estimates.

During the second quarter, those charges reduced EPS by USD 3.03, yet non-GAAP earnings reached USD 8.38 compared with approximately USD 6.58 expected. The drop from USD 9.87 to USD 6.67 equals about USD 3.20 by arithmetic. Revenue is therefore the more comparable operating benchmark.

Can Tirzepatide Volume Outrun Pricing and Competitive Pressure?

Second-quarter sales increased 47.7% to USD 22.97 billion. Mounjaro advanced 91% to USD 9.94 billion, while Zepbound grew 46% to USD 4.93 billion. International Mounjaro sales rose 172%, providing an important volume counterweight to lower prices.

Excluding rebate adjustments, US prices declined approximately 9% in that quarter. Management’s finance chief said volume growth should outweigh the pricing decline, but Novo Nordisk (NYSE:NVO) remains a competitive risk. A beat without higher guidance could disappoint because consensus exceeds the range ceiling by USD 1.68 billion.

What to Watch Next: Which October 28 to 29 Signals Could Prompt a Raise?

The Fed decides Wednesday, October 28, before Lilly’s Thursday report. Investors will seek guidance and early Foundayo demand evidence. They will also assess the timetable for a retatrutide filing targeted for the first quarter of 2027.

Options price an approximate 6.6% move in either direction, while the shares lost about 3.3% on Friday, October 23, 2026. Past reactions show the expectations risk: the stock fell 14.14% on its second-quarter 2025 report day even though EPS beat estimates.

Charge timing can make the headline EPS appear weak even when drug demand remains strong. Further US price reductions, competition and failure to lift the sales range are the main risks. Consensus figures and implied moves are estimates rather than assurances.

The third-quarter sales figure will help distinguish operating demand from accounting noise. If Mounjaro and Zepbound volumes continue to expand while acquired research costs depress EPS, revenue may offer the clearer signal of underlying momentum.

A third guidance increase would also need to address pricing quality. International growth of 172% is supportive, but the 9% US price decline means volume must do more work. The balance between those forces will determine whether growth can support the market’s USD 88.7 billion rounded expectation.